CoreValve US Pivotal TrialHigh-Risk Arm

Device and Access Routes

End Points

Patient Eligibilitya

Study Disposition

Baseline Demographics

Results 1 Year All-Cause Mortality

Results Noninferiority and Superiority

Results 2-Year All-cause Mortality (Preliminary Results)

Clinical Patient Outcomes

Results All Stroke

Secondary End Points

1-Year MACCE

Other End Points

Paravalvular Regurgitation

Subgroup Analysis1 Year

Subgroup Analysis1 Year (cont)

Conclusion

CoreValve US Pivotal Trial In Context

What Did We Learn?

Surgical Outcomes

Patient SelectionWhat Is High Risk?

Key Inclusion Criteria

Study Population – In Context

Expanded Patient Population

Loss to Follow-Up: Sensitivity Analyses

Future TAVR vs SAVR Trial Design Considerations

TAVR in Community Practice

The TVT Registry

TVT 1-Year Outcomesa

TAVR Device Comparison Trials

CHOICE Key Outcomes

CHOICEClinical Implications

TAVR in Clinical Practice: Moving Forward

Abbreviations

Abbreviations (cont)

References

References (cont)